LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivaNova PLC on September 3, 2025. The report discloses the appointment of a new director to the Board of Directors effective September 4, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Donald Zurbay as a Director and member of the Audit and Compliance Committee. Mr. Zurbay brings over 20 years of healthcare leadership experience, most recently serving as CEO and CFO of Patterson Companies, Inc., and previously holding senior roles at St. Jude Medical, Inc.
Compensation and Governance Details
Mr. Zurbay's compensation package, prorated until the 2026 Annual General Meeting, includes:
- Annual board retainer fee: $70,000
- Audit and Compliance Committee annual member fee: $15,000
- Annual service-based restricted stock award grant with a fair market value of $185,000
The filing states there are no undisclosed arrangements regarding his selection and no transactions involving the Company since January 1, 2024.
Investor Verification Checklist
- Verify the effective date of Mr. Zurbay's term (September 4, 2025).
- Confirm the prorated calculation of the $270,000 total annual cash and equity compensation for the partial year.
- Review the Company's Remuneration Policy to understand the vesting schedule for the restricted stock award.
- Check subsequent filings for any updates to the Board composition or committee assignments.